DQS: The New Evolution of dd-cfDNA Testing and Noninvasive Rejection Monitoring, Presented by Natera

Jun 26, 2025

In this episode of the ISHLT Voices podcast, hosted by Natera, you’ll hear transplant cardiologists explore the evolving landscape of post-heart transplant care, zeroing in on the transformative shift from traditional, invasive biopsies to cutting-edge noninvasive molecular diagnostics—particularly cell-free DNA technologies.

Brent Lampert, DO

Medical Director, Transplant Cardiologist
The Ohio State University Wexner Medical Center  
Columbus, OH USA

 

 

Ajith P. Nair, MD, FACC, FAHA

Associate Professor, Medicine—Cardiology
Texas Heart Institute at Baylor College of Medicine
Houston, TX USA

 

Drs. Lampert and Nair discuss the clinical promise of tools like Natera’s Prospera Heart with Donor Quantity Score (DQS), which not only offer heightened accuracy and earlier detection of graft injury and rejection, but also may empower clinicians to strike a vital balance: preventing rejection without over-immunosuppression.

Real-world insights, compelling case examples, and candid discussions about the challenges of biopsy-based monitoring—and how new technology is reshaping decisions, outcomes, and patient peace of mind—make this a must-listen for anyone intrigued by the future of transplantation medicine.

 

The content of this podcast was developed entirely by our industry partner, Natera. It is not an official educational program of the ISHLT, and therefore is not eligible for CME under the ISHLT.

This episode was created for ISHLT Voices and sponsored by Natera.